



(12) Translation of
European patent specification

(11) NO/EP 3466949 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2021.05.31

(80) Date of The European Patent Office Publication of the Granted Patent 2020.12.23

(86) European Application Nr. 18192207.1

(86) European Filing Date 2014.12.23

(87) The European Application's Publication Date 2019.04.10

(30) Priority 2013.12.24, US, 201361920500 P

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

(62) Divided application EP3087071, 2014.12.23

(73) Proprietor Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA

(72) Inventor NORRIS, Derek J., Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
DELUCCA, George V., Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
GAVAI, Ashvinikumar V., Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
QUESNELLE, Claude A., Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
GILL, Patrice, Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
O'MALLEY, Daniel, Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
VACCARO, Wayne, Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
LEE, Francis Y., Bristol-Myers Squibb Company,Route 206 & Province Line Road, Princeton, NJ 08543, USA
DEBENEDETTO, Mikkel V., Bristol-Myers Squibb Company,5 Research Parkway, Wallingford, Connecticut 06492, USA
DEGNAN, Andrew P., Bristol-Myers Squibb Company,5 Research Parkway, Wallingford, Connecticut 06492, USA
FANG, Haiquan, 304 County Road, Madison, Connecticut 06443, USA
HILL, Matthew D., Bristol-Myers Squibb Company,5 Research Parkway, Wallingford, Connecticut 06492, USA

HUANG, Hong, 475 Powder Hill Road, Durham, Connecticut 06422, USA
SCHMITZ, William D., Bristol-Myers Squibb Company, 5 Research Parkway,
Wallingford, Connecticut 06492, USA
STARRETT, JR, John E., 132 Niantic River Road, Waterford, Connecticut 06385,
USA
HAN, Wen-Ching, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford,
Connecticut 06492, USA
TOKARSKI, John S., Bristol-Myers Squibb Company, 5 Research Parkway,
Wallingford, Connecticut 06492, USA
MANDAL, Sunil Kumar, Syngene International Limited, Biocon Park, Plot Nos.
2&3, Bommasandra IV Phase, Jigani Link Road, Bangalore, Karnataka 56009, India

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **TRICYCLIC COMPOUND AS ANTICANCER AGENTS**

(56) References


Cited:

WO-A1-2012/145173
WO-A1-2013/046635
WO-A1-2014/086739
WO-A1-2014/134232
WO-A1-2014/134267
WO-A1-2014/164596
CONWAY: ACS MED. CHEM. LETT., vol. 3, 2012, pages 691-694, XP055124436,
HEWINGS ET AL.: J. MED. CHEM., vol. 55, 2012, pages 9393-9413, XP055124430,
GÖRLITZER K ET AL: "Reaktionen von 4,5-Dihydro-4-oxo-1H-pyrido(3,2-b)indol-2-
carbonsäure-estern 1-3", DIE PHARMAZIE, GOVI VERLAG PHARMAZEUTISCHER VERLAG
GMBH, ESCHBORN, DE, vol. 55, no. 4, 1 January 2000 (2000 -01-01), pages 273-281,
XP001526711, ISSN: 0031-7144

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav

1. En forbindelse som har formelen



5

2. Et farmasøytisk akseptabelt salt av en forbindelse som har strukturen



10 **3.** En farmasøytisk sammensetning som omfatter en forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav og ett eller flere farmasøytisk akseptable bærere, fortynningsmidler eller hjelpestoffer.

d

15 **4.** Forbindelsen ifølge krav 1, for bruk i behandling av kreft i en pasient, hvor kreften er småcelle lungekreft, ikke-småcelle lungekreft, kolorektalkreft, multippel myelom eller AML.

20 **5.** Det farmasøytisk akseptable saltet ifølge krav 2, for bruk i behandling av kreft i en pasient, hvor kreften er småcelle lungekreft, ikke-småcelle lungekreft, kolorektalkreft, multippel myelom eller AML.